Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases
Main Article Content
Keywords
pemphigus, immunoglobulins, autoimmune, efgartigimod, FcRn, Dsg-1, Dsg-3, IgG, bullous pemphigoid, BP-180, BP-230
References
1. Sesarman A, et al. Cell Mol Life Sci. 2010;67:2533–50.
2. Ulrichts P, et al. J Clin Invest. 2018;128:4372–86.
3. Vaccaro C, et al. Nat Biotech. 2005;23:1283–88.
4. Newland AC, et al. Am J Hematol. 2020;95:178–87.
5. Goebeler M, et al. Br J Dermatol. 2022;10:1111.
6. Howard JF Jr, et al. Lancet Neurol. 2021;20:526–36.
7. argenx, Inc. (March 22, 2022). Topline Results: ADAPT-SC Bridging Study in gMG.
8. argenx, Inc. (May 5, 2022). Topline Results: ADVANCE study in ITP.
9. Schmidt E, et al. Lancet. 2019;394:882.
10. Amagai M, et al. J Am Acad Dermatol. 1999;40:167–70.
11. Kridin K, et al. Front Med (Laussane). 2018;5:220.
2. Ulrichts P, et al. J Clin Invest. 2018;128:4372–86.
3. Vaccaro C, et al. Nat Biotech. 2005;23:1283–88.
4. Newland AC, et al. Am J Hematol. 2020;95:178–87.
5. Goebeler M, et al. Br J Dermatol. 2022;10:1111.
6. Howard JF Jr, et al. Lancet Neurol. 2021;20:526–36.
7. argenx, Inc. (March 22, 2022). Topline Results: ADAPT-SC Bridging Study in gMG.
8. argenx, Inc. (May 5, 2022). Topline Results: ADVANCE study in ITP.
9. Schmidt E, et al. Lancet. 2019;394:882.
10. Amagai M, et al. J Am Acad Dermatol. 1999;40:167–70.
11. Kridin K, et al. Front Med (Laussane). 2018;5:220.